Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease-Reference-Cited by-同舟云学术

Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease

Published:2018 Issue:1 Volume:59 Page:105-111
ISSN:1349-2365
Container-title:International Heart Journal
language:en
Short-container-title:Int. Heart J.

Author:

Nakano Yusuke¹,Mizuno Tomofumi¹,Niwa Toru¹,Mukai Kentaro¹,Wakabayashi Hirokazu¹,Watanabe Atsushi¹,Ando Hirohiko¹,Takashima Hiroaki¹,Murotani Kenta²,Waseda Katsuhisa¹,Amano Tetsuya¹

Affiliation:

1. Department of Cardiology, Aichi Medical University

2. Division of Biostatistics, Clinical Research Center, Aichi Medical University

Publisher

International Heart Journal (Japanese Heart Journal)

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/ihj/59/1/59_16-625/_pdf

Reference29 articles.

1. 1. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, et al. Chronic kidney disease as an independent risk for long-term adverse outcomes in patients hospitalized with heart failure in Japan. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1442-7.

2. 2. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. Am J Cardiol 2000; 85: 1110-3.